A review of ropinirole prolonged release in Parkinson’s disease

Código QR

A review of ropinirole prolonged release in Parkinson’s disease

Muhammad M Nashatizadeh, Kelly E Lyons, Rajesh PahwaDepartment of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USAAbstract: Ropinirole prolonged release is a once-daily, 24-hour formulation of ropinirole, a non-ergot dopamine agonist. It is approved as monotherapy and as an a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammad M Nashatizadeh, Kelly E Lyons, Rajesh Pahwa
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	ropinirole prolonged release ropinirole PR dopamine agonist Parkinson's disease once-daily treatment Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/9df572a6b87b430eacb1de5fbc299229
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Adverse drug reaction suggests by a clinical vignette
por: Finestone AJ
Publicado: (2011)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller T
Publicado: (2018)

Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
por: Szász JA, et al.
Publicado: (2019)

Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
por: Juri C,Carlos, et al.
Publicado: (2006)

Pharmacological methods of therapy in Parkinson’s disease
por: Y. N. Bykov, et al.
Publicado: (2016)

A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients
por: Uta Herden, et al.
Publicado: (2021)

Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina
por: Cuevas,José Luis, et al.
Publicado: (2013)

The Retinal Posterior Pole in Early Parkinson’s Disease: A Fundus Perimetry and SD-OCT Study
por: Cesareo M, et al.
Publicado: (2021)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Síndrome de piernas inquietas (enfermedad de Willis-Ekbom): seguimiento a largo plazo de una serie de pacientes
por: Miranda C,Marcelo, et al.
Publicado: (2016)

Update on ropinirole in the treatment of Parkinson&rsquo;s disease
por: Holly A Shill, et al.
Publicado: (2008)

Diagnóstico precoz de enfermedad de Parkinson: neurospect del transportador de Dopamina
por: Díaz,Fernando, et al.
Publicado: (2002)

The role of rasagiline in the treatment of Parkinson’s disease
por: Julie Leegwater-Kim, et al.
Publicado: (2010)

Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
por: Petrò E, et al.
Publicado: (2016)

Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson’s disease
por: Mao CJ, et al.
Publicado: (2017)

Severo edema inducido por la terapia dopaminérgica en la enfermedad de Parkinson. Caso clínico
por: Miranda C.,Marcelo, et al.
Publicado: (2017)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
por: Hametner EM, et al.
Publicado: (2012)

Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter‐mediated nonquantal dopamine release
por: Viktor Román, et al.
Publicado: (2021)

Association between a frailty index based on common laboratory tests and QTc prolongation in older adults: the Rugao Longevity and Ageing Study
por: Ma T, et al.
Publicado: (2018)

Systematic review on strength training in Parkinson’s disease: an unsolved question
por: Ramazzina I, et al.
Publicado: (2017)

Using Graphene-Based Biosensors to Detect Dopamine for Efficient Parkinson’s Disease Diagnostics
por: Małgorzata Kujawska, et al.
Publicado: (2021)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010)

Dopamine, a co-regulatory component, bridges the central nervous system and the immune system
por: Mingan Li, et al.
Publicado: (2022)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via MA
Publicado: (2010)

Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial
por: R. Matthew Hutchison, et al.
Publicado: (2021)

Sex-related differences in homebound advanced Parkinson’s disease patients
por: Nwabuobi L, et al.
Publicado: (2019)

Clinical study of the effects of deep brain stimulation on urinary dysfunctions in patients with Parkinson’s disease
por: Zong H, et al.
Publicado: (2019)

A practical method for the detection of freezing of gait in patients with Parkinson’s disease
por: Kwon Y, et al.
Publicado: (2014)

Different protocols for analyzing behavior and adaptability in obstacle crossing in Parkinson’s disease
por: Mollaei N, et al.
Publicado: (2017)

Designing pH-Dependent Systems Based on Nanoscale Calcium Carbonate for the Delivery of an Antitumor Drug
por: Victoriya Popova, et al.
Publicado: (2021)

Progressive Resistance Training Improves Bradykinesia, Motor Symptoms and Functional Performance in Patients with Parkinson’s Disease
por: Vieira de Moraes Filho A, et al.
Publicado: (2020)

Minimum Alveolar Concentration-Awake of Sevoflurane is Decreased in Patients with Parkinson’s Disease: An Up-and-Down Sequential Allocation Trial
por: Yang C, et al.
Publicado: (2021)

Aquatic Environment Exposure and Toxicity of Engineered Nanomaterials Released from Nano-Enabled Products: Current Status and Data Needs
por: Mbuyiselwa Shadrack Moloi, et al.
Publicado: (2021)

Effect of Clofibrate on Prolonged Jaundice of Term Neonates
por: Y Zahed pasha,, et al.
Publicado: (2009)

How do demographic transitions and public health policies affect patients with Parkinson’s disease in Brazil?
por: Bovolenta TM, et al.
Publicado: (2017)

The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients
por: Hyoeun Bae, et al.
Publicado: (2021)

Effects of carbonated liquid on swallowing dysfunction in dementia with Lewy bodies and Parkinson’s disease dementia
por: Larsson V, et al.
Publicado: (2017)

Parkinson's disease

SARS-COV-2 induced Parkinsonism: The first case from the sub-Saharan Africa
por: Biniyam A. Ayele, et al.
Publicado: (2021)

Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson’s disease: pilot study
por: Carvalho A, et al.
Publicado: (2015)